Go Pro

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Given Average Rating of "Buy" by Analysts

Bayer Aktiengesellschaft logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Bayer has a consensus “Buy” rating from eight analysts: five recommend buying, two strongly recommend buying and one advises holding. Several firms recently upgraded their ratings, including DZ Bank and Zacks Research to “strong buy.”
  • BAYRY shares opened at $14.35, up 0.9%, with a market capitalization of approximately $56.38 billion. The stock has traded between $7.48 and $15.23 over the past year.
  • Bayer exceeded quarterly expectations, reporting $0.29 in EPS versus the $0.23 estimate and revenue of $12.53 billion versus $12.31 billion expected. Management issued fiscal 2026 EPS guidance of $1.20–$1.346.
  • MarketBeat previews the top five stocks to own by October 1st.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) has earned a consensus rating of "Buy" from the eight analysts that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and two have issued a strong buy recommendation on the company.

Several analysts have recently commented on BAYRY shares. Jefferies Financial Group upgraded Bayer Aktiengesellschaft to a "hold" rating in a report on Friday, May 29th. DZ Bank raised Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 19th. Zacks Research upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research report on Friday, July 10th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a report on Thursday, July 2nd.

Check Out Our Latest Stock Report on BAYRY

Bayer Aktiengesellschaft Stock Up 0.9%

Shares of BAYRY opened at $14.35 on Friday. The company has a market capitalization of $56.38 billion, a P/E ratio of -28.13, a PEG ratio of 4.46 and a beta of 0.56. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.05 and a quick ratio of 0.70. Bayer Aktiengesellschaft has a one year low of $7.48 and a one year high of $15.23. The business's 50 day simple moving average is $13.99 and its 200-day simple moving average is $12.23.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.29 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.06. Bayer Aktiengesellschaft had a positive return on equity of 17.00% and a negative net margin of 3.80%.The firm had revenue of $12.53 billion during the quarter, compared to analysts' expectations of $12.31 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, sell-side analysts predict that Bayer Aktiengesellschaft will post 1.28 EPS for the current fiscal year.

About Bayer Aktiengesellschaft

(Get Free Report)

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women's health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.

Featured Articles

Analyst Recommendations for Bayer Aktiengesellschaft (OTCMKTS:BAYRY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Bayer Aktiengesellschaft Right Now?

Before you consider Bayer Aktiengesellschaft, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bayer Aktiengesellschaft wasn't on the list.

While Bayer Aktiengesellschaft currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines